Tac2‑N serves an oncogenic role and promotes drug resistance in human gastric cancer cells

Shen,Lei; Zhang,Pingping; Wang,Jianbing; Ji,Peng

doi:10.3892/etm.2020.9241

Tac2‑N serves an oncogenic role and promotes drug resistance in human gastric cancer cells

Authors:
- Lei Shen
- Pingping Zhang
- Jianbing Wang
- Peng Ji
View Affiliations

Affiliations: Department of Oncology, The Third People's Hospital of Hefei, Hefei, Anhui 230051, P.R. China, Department of Physiology, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Magnetic Resonance, The Third People's Hospital of Hefei, Hefei, Anhui 230051, P.R. China
Published online on: September 18, 2020 https://doi.org/10.3892/etm.2020.9241
Article Number: 113
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is one of the most common types of malignancy worldwide. Tac2‑N (TC2N) has been reported to serve as either an oncogene or tumor suppressor in numerous different types of cancer; however, the role of TC2N in gastric cancer remains poorly understood. The present study aimed to investigate the role of TC2N in gastric cancer and reveal its regulatory mechanism. A Cell Counting Kit‑8 assay was used to analyze the cell proliferation rate, while wound healing and Transwell Matrigel assays were performed to determine the cell migratory and invasive abilities, respectively. Cell cycle distribution was determined by flow cytometric analysis, and the expression levels of TC2N, P‑glycoprotein (P‑gp), cyclin D1, CDK4, cyclin E1, MMP2, MMP9 and N‑Myc downstream regulated gene 1 were analyzed using reverse transcription‑quantitative PCR or western blotting. Bioinformatics analysis revealed a high expression of TC2N in patients with gastric cancer. The experimental results revealed that TC2N expression levels were significantly unregulated in gastric cancer cell lines. The knockdown of TC2N in AGS cells significantly inhibited the cell proliferation rate and induced cell cycle arrest at the G0/G1 phase, while downregulating cyclin E1, cyclin D1 and CDK4 expression levels. The knockdown of TC2N also inhibited cell migration and invasion. Furthermore, the knockdown of TC2N improved the sensitivity of AGS cells to cisplatin, paclitaxel and 5‑fluorouracil, and downregulated the protein expression levels of P‑gp. By contrast, TC2N overexpression exerted the opposite effects in AGS cells. In conclusion, the findings of the present study indicated that the genetic knockdown of TC2N may inhibit cell proliferation, migration and invasion, while inducing cell cycle arrest in the G1/S phase and reversing the drug resistance of AGS cells, which may be partly through inhibiting P‑gp expression levels. Thus, TC2N may serve as a novel diagnostic marker and therapeutic target for patients with gastric cancer.

View Figures

View References

1	Song Z, Wu Y, Yang J, Yang D and Fang X: Progress in the treatment of advanced gastric cancer. Tumour Biol. 39(1010428317714626)2017.PubMed/NCBI View Article : Google Scholar
2	Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality (1980-2011), with predictions to. 2015, and incidence by subtype. Eur J Cancer. 50:1330–1344. 2014.PubMed/NCBI View Article : Google Scholar
3	Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA and Psyrri A: Medical management of gastric cancer: A 2017 update. Cancer Med. 7:123–133. 2018.PubMed/NCBI View Article : Google Scholar
4	Russo A, Li P and Strong VE: Differences in the multimodal treatment of gastric cancer: East versus west. J Surg Oncol. 115:603–614. 2017.PubMed/NCBI View Article : Google Scholar
5	Hamashima C: Current issues and future perspectives of gastric cancer screening. World J Gastroenterol. 20:13767–13774. 2014.PubMed/NCBI View Article : Google Scholar
6	Hao XL, Han F, Zhang N, Chen HQ, Jiang X, Yin L, Liu WB, Wang DD, Chen JP, Cui ZH, et al: TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer. Cell Death Differ. 26:1235–1250. 2019.PubMed/NCBI View Article : Google Scholar
7	Farah CA and Sossin WS: The role of C2 domains in PKC signaling. Adv Exp Med Biol. 740:663–683. 2012.PubMed/NCBI View Article : Google Scholar
8	Kabekkodu SP, Bhat S, Radhakrishnan R, Aithal A, Mascarenhas R, Pandey D, Rai L, Kushtagi P, Mundyat GP and Satyamoorthy K: DNA promoter methylation-dependent transcription of the double C2-like domain β (DOC2B) gene regulates tumor growth in human cervical cancer. J Biol Chem. 289:10637–10649. 2014.PubMed/NCBI View Article : Google Scholar
9	Choi HY, Park N, Na JB, Ko ES, Park JY and Yoo JC: Direct binding of Copine3 with Jab1 activates downstream ErbB2 signaling and motility in SKBr3 breast cancer cells. Oncol Rep. 35:1147–1152. 2016.PubMed/NCBI View Article : Google Scholar
10	Hao X, Gao LY, Zhang N, Chen H, Jiang X, Liu W, Ao L, Cao J, Han F and Liu J: Tac2-N acts as a novel oncogene and promotes tumor metastasis via activation of NF-κB signaling in lung cancer. J Exp Clin Cancer Res. 38(319)2019.PubMed/NCBI View Article : Google Scholar
11	Hao XL, Gao LY, Deng XJ, Han F, Chen HQ, Jiang X, Liu WB, Wang DD, Chen JP, Cui ZH, et al: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer. Cell Death Dis. 10(424)2019.PubMed/NCBI View Article : Google Scholar
12	Tomczak K, Czerwińska P and Wiznerowicz M: The cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI View Article : Google Scholar
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
14	Wang X, Yang B, She Y and Ye Y: The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 119:7790–7799. 2018.PubMed/NCBI View Article : Google Scholar
15	Tian S, Wang X and Proud CG: Oncogenic MNK signalling regulates the metastasis suppressor NDRG1. Oncotarget. 8:46121–46135. 2017.PubMed/NCBI View Article : Google Scholar
16	Fu Y, Wei J, Dai X and Ye Y: Increased NDRG1 expression attenuate trophoblast invasion through ERK/MMP-9 pathway in preeclampsia. Placenta. 51:76–81. 2017.PubMed/NCBI View Article : Google Scholar
17	Battistella C and Klok HA: Reversion of P-gp-mediated drug resistance in ovarian carcinoma cells with PHPMA-zosuquidar conjugates. Biomacromolecules. 18:1855–1865. 2017.PubMed/NCBI View Article : Google Scholar
18	Ciesielski M, Kruszewski WJ, Walczak J, Szajewski M, Szefel J, Wydra J, Buczek T and Czerepko M: Analysis of postoperative morbidity and mortality following surgery for gastric cancer. Surgeon volume as the most significant prognostic factor. Prz Gastroenterol. 12:215–221. 2017.PubMed/NCBI View Article : Google Scholar
19	Willmer T, Peres J, Mowla S, Abrahams A and Prince S: The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2. Cell Cycle. 14:3173–3183. 2015.PubMed/NCBI View Article : Google Scholar
20	Wen Q, Luo K, Huang H, Liao W and Yang H: Xanthoxyletin inhibits proliferation of human oral squamous carcinoma cells and induces apoptosis, autophagy, and cell cycle arrest by modulation of the MEK/ERK signaling pathway. Med Sci Monit. 25:8025–8033. 2019.PubMed/NCBI View Article : Google Scholar
21	Galderisi U, Jori FP and Giordano A: Cell cycle regulation and neural differentiation. Oncogene. 22:5208–5219. 2003.PubMed/NCBI View Article : Google Scholar
22	Liu W, Hua S, Dai Y, Yuan Y, Yang J, Deng J, Huo Y, Chen X, Teng B, Yu X and Zhang Y: Roles of Cx43 and AKAP95 in ovarian cancer tissues in G1/S phase. Int J Clin Exp Pathol. 8:14315–14324. 2015.PubMed/NCBI
23	Yao Y, Yang X, Sun L, Sun S, Huang X, Zhou D, Li T, Zhang W, Abumrad NA, Zhu X, et al: Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancer. EBioMedicine. 41:256–267. 2019.PubMed/NCBI View Article : Google Scholar
24	Luo Y, Zha L, Luo L, Chen X, Zhang Q, Gao C, Zhuang X, Yuan S and Qiao T: [6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway. Phytother Res. 33:1353–1362. 2019.PubMed/NCBI View Article : Google Scholar
25	Wei X, Gao M, Ahmed Y, Gao M, Liu W, Zhang Y, Xie X, Zhao Q, Wang H and Gu K: MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein. Oncol Lett. 18:1607–1616. 2019.PubMed/NCBI View Article : Google Scholar
26	Yang Q, Zhu C, Zhang Y, Wang Y, Wang Y, Zhu L, Yang X, Li J, Nie H, Jiang S, et al: Molecular analysis of gastric cancer identifies genomic markers of drug sensitivity in Asian gastric cancer. J Cancer. 9:2973–2980. 2018.PubMed/NCBI View Article : Google Scholar
27	Liu F, Yin R, Chen X, Chen W, Qian Y, Zhao Y, Jiang Y, Ma D, Hu T, Yu T, et al: Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother. 114(108605)2019.PubMed/NCBI View Article : Google Scholar
28	Cantore M, Capparelli E, Berardi F, Perrone R and Colabufo NA: Clinical pharmacokinetic and metabolism of PET radiotracers for imaging P-glycoprotein in chemoresistant tumor of colorectal cancer. Curr Drug Metab. 12:985–988. 2011.PubMed/NCBI View Article : Google Scholar
29	Tan B, Li Y, Zhao Q, Fan L and Wang D: ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185. Biosci Rep. 38(BSR20181023)2018.PubMed/NCBI View Article : Google Scholar